Document:

Exhibit 10.29

 Exhibit 10.29 

 

			
		
	

	    	

 USA Mobility, Inc. 
 2012 Short-Term Incentive Plan 
 (Effective January 1, 2012) 

 

	I.	Effective Date. The 2012 Short-Term Incentive Plan (the “Plan”) for USA Mobility, Inc., (the “Company”) was adopted by the Compensation
Committee of the Board of Directors (the “Board”) of USA Mobility, Inc., (the “Parent”), a Delaware corporation for the employees of USA Mobility Wireless, Inc., a Delaware corporation and a subsidiary of the Parent, and for
Amcom Software, Inc., a Delaware corporation and a subsidiary of the Parent on December 1, 2011. The Plan is effective as of January 1, 2012 and supersedes and replaces all former management short-term incentive plans, including the USA
Mobility Wireless, Inc., 2011 Short-Term Incentive Plan and the Amcom Software, Inc. 2011 Short Term Incentive Plan. 

  

	II.	Purpose. The Plan is designed to attract, motivate, retain and reward key employees for their performance during the calendar year, from January 1 through
December 31, 2012 (the “Performance Period”). The Plan rewards key employees by allowing them to receive cash bonuses based on how well the Company performs against the performance objectives selected by the Board and set forth in
Exhibit A (the “Performance Objectives”), as may be adjusted by the Board in the event of a Change of Control or other corporate reorganization, merger, similar transaction, to take into account extraordinary events or as the Committee
determines is in the best interests of the Company. In order for bonuses to be earned, the Company must meet the Performance Objectives as outlined on Exhibit A on December 31, 2012. Performance Objectives are based solely on the performance of
USA Mobility Wireless, Inc. and its affiliate Metrocall Ventures, Inc. and its subsidiaries and Amcom Software, Inc. and its subsidiary Commtech Wireless Pty, LTD. For clarity, Performance Objectives and the attainment thereof does not include
revenue or expenses related to acquisitions or due diligence occurring after the Effective Date of this Plan except as directed by the Compensation Committee. 

 

	III.	Eligibility. Participation in the Plan is limited to those key employees who are selected for participation in the Plan by the Board, in its sole discretion
(each such individual, a “Participant”). Individuals selected by the Board to participate as of January 1, 2012 are listed on Exhibit B. Newly hired or promoted employees, or employees who otherwise become eligible to
participate, who are selected to participate in the Plan after January 1, 2012 but before October 1, 2012 will participate in the Plan on a prorated basis based on the number of days worked during the performance period after becoming
bonus eligible. Employees who are newly hired or promoted on or after October 1, 2012 will not be eligible to participate in the Plan. 

  

	IV.	Target Bonus. The target bonus for each Participant is based on a percentage of the Participant’s annual (or prorated, if applicable) salary as of
January 1, 2012 (or date of hire or promotion to an eligible position, if later). The applicable percentage is determined by the Compensation Committee with respect to executives earning $250,000 or more and by the CEO for other management and
need not be identical among Participants. The earned bonus may be greater than or less than the target bonus depending on the level at which the Performance Objectives are attained. For 2012, in order for the CEO of USA Mobility, Inc., to earn more
than 100% of his target bonus, both operating subsidiaries must attain at least 95% of their Operating Cash Flow (OCF) target. In addition, for 2012, in order for all other Participants (excluding the CEO of USA Mobility, Inc.) to earn more than
100% of their target bonus, their respective operating entity must achieve at least 95% of its Operating Cash Flow (OCF) target. 

  
 1 

			
		
	

	    	

  

	V.	Payment of Earned Bonus. 

  

	 	a.	Except as provided herein, each earned bonus under the Plan will be calculated based on the attainment of the Performance Objectives and will be paid in a lump sum
(subject to any required withholding for income and employment taxes) after the 2012 annual audit of the Parent’s consolidated financial statement has been completed and the Parent’s annual report on Form 10K has been filed with the
Securities and Exchange Commission but in no event later than December 31, 2013. 

  

	 	b.	If the Participant involuntarily Separates from Service without Cause or due to disability or dies prior to December 31, 2012, he or she will be eligible to
receive a prorated bonus provided that the Company is on track to attain the Performance Objectives as reasonably determined by the Compensation Committee and provided further that, in the event Participant involuntarily Separates from Service
without Cause, he or she has executed a release, any waiting period in connection with such release has expired, he or she has not exercised any rights to revoke the release and he or she has followed any other applicable and customary termination
procedures, as determined by the Parent in its sole discretion. The bonus will be prorated to the date of Participant’s Separation from Service or death, calculated as follows: one-hundred percent (100%) of a Participant’s target
bonus will be multiplied by a fraction, the numerator of which is the number of days the Participant was continuously providing services to the Company from January 1, 2012 through the date immediately prior to the Participant’s Separation
from Service or death, and the denominator of which is 366 days. Prorated bonuses will be paid to the Participant, or in the event of Participant’s death, the Participant’s estate, on the sixty-fifth (65th) day following the date of
Participant’s Separation from Service or death. 

  

	 	i.	 For purposes of the Plan, “Separation from Service” shall have the meaning provided in the Treasury Regulations under section 409A of the
Internal Revenue Code of 1986, as amended (the “Code”), and “Separates from Service” shall have a consistent meaning. Unless otherwise defined in an employment agreement between the Participant and the Parent or the Company, for
purposes of the Plan, “Cause” means (i) dishonesty of a material nature that relates to the performance of services for the Company by Participants; (ii) criminal conduct (other than minor infractions and traffic violations) that
relates to the performance of services for the Company by Participant; (iii) the Participant’s willfully breaching or failing to perform his or her duties as an employee of the Company (other than any such failure resulting from the
Participant having a disability (as defined herein)), within a reasonable period of time after a written demand for substantial performance is delivered to the Participant by the Board, which demand specifically identifies the manner in which the
Board believes that the Participant has not substantially performed his duties; or (iv) the willful engaging by the Participant in conduct that is demonstrably and materially injurious to the Parent, Company or an Affiliate, monetarily or
otherwise. No act or failure to act on the Participant’s part shall be deemed “willful” unless done, or omitted to be done; by the Participant not in good faith and without reasonable belief that such action or omission was in the
reasonable best interests of the Parent, Company and Affiliates. For this purpose, “disability” means a 

  
 2 

			
		
	

	    	

  

	 	
condition or circumstance such that the Participant has become totally and permanently disabled as defined or described in the Parent’s long term disability benefit plan applicable to
executive officers as in effect at the time the Participant incurs a disability. 

  

	 	c.	Notwithstanding anything to the contrary in this Plan, no payments contemplated by this Plan will be paid during the six-month period following a Participant’s
Separation from Service unless the Company determines, in its good faith judgment, that paying such amounts at the time indicated in paragraph B above would not cause the Participant to incur an additional tax under Code section 409A (a)(2)(B)(i),
in which case the bonus payment shall be paid in a lump sum on the first day of the seventh month following the Participant’s Separation from Service. 

 

	VI.	Forfeiture. Any Participant whose employment is terminated for Cause or who voluntarily Separates from Service prior to the date bonuses are paid shall forfeit
any right to receive a bonus award. 

  

	VII.	Administrator. The Compensation Committee of the Board shall administer the Plan in accordance with its terms, and shall have full discretionary power and
authority to construe and interpret the Plan; to prescribe, amend and rescind rules and regulations, terms, and notices hereunder; and to make all other determinations necessary or advisable in its discretion for the administration of the Plan. Any
actions of the Compensation Committee with respect to the Plan shall be conclusive and binding upon all persons interested in the Plan. The Compensation Committee, in its sole discretion and on such terms and conditions as it may provide, may
delegate all or part of its authority and powers under the Plan to one or more directors and/or officers of the Parent or the Company. 

  

	VIII.	Amendment; Termination. The Board, in its sole discretion, without prior notice to Participants, may amend or terminate the Plan, or any part thereof, including
the Performance Objectives as described in Section II, at any time and for any reason, to the extent such action will not cause adverse tax consequences to a participant under Code section 409A. Any amendment or termination must be in writing and
shall be communicated to all Participants. No award may be granted during any period of suspension or after termination of the Plan. 

  

	IX.	Miscellaneous. 

  

	 	a.	No Rights as Employee. Nothing contained in this Plan or any documents relating to this Plan shall (a) confer on a Participant any right to continue in the
employ of the Company; (b) constitute any contract or agreement of employment; or (c) interfere in any way with the Company’s right to terminate the Participant’s employment at any time, with or without Cause.

  

	 	b.	Tax Withholding. To the extent required by applicable federal, state, local or foreign law, the Company shall withhold all applicable taxes (including, but not
limited to, the Participant’s FICA and Social Security obligations) from any bonus payment. 

  

	 	c.	Transferability. A Participant may not sell, assign, transfer or encumber any of his or her rights under the Plan. 

  
 3 

			
		
	

	    	

  

	 	d.	Unsecured General Creditor. Participants (or their beneficiary) may seek to enforce any rights or claims for payment under the Plan solely as an unsecured
general creditor of the Parent or Company. 

  

	 	e.	Successors. This Plan shall be binding upon and inure to the benefit of the Parent, Company and any successor to the Company and the Participant’s heirs,
executors, administrators and legal representatives. 

  

	 	f.	Code Section 409A. The Plan is intended to be a nonqualified deferred compensation plan within the meaning of Code section 409A and shall be interpreted to
meet the requirements of Code section 409A. To the extent that any provision of the Plan would cause a conflict with the requirements of Code section 409A, or would cause the administration of the Plan to fail to satisfy Code section 409A, such
provision shall be deemed null and void to the extent permitted by applicable law. Nothing herein shall be construed as a guarantee of any particular tax treatment to a Participant. 

 

	 	g.	Governing Law. All questions pertaining to the validity, construction and administration of the Plan shall be determined in accordance with the laws of the State
of Delaware, without regard to conflicts of law provisions. 

  

	 	h.	Integration. This document and each exhibit hereto represent the entire agreement and understanding between the Company and the Participants and supersede any
and all prior agreements or understandings, whether oral or written, with the Company relating to the subject matter covered by this Plan. 

  

	 	i.	Severability. In case any provision of this Plan shall be held illegal or invalid, such illegality or invalidity shall be construed and enforced as if said
illegal or invalid provision had never been inserted herein and shall not affect the remaining provisions of this Plan, but shall be fully severable, and the Plan shall be construed and enforced as if any such illegal or invalid provision were not a
part hereof. 

 [Execution page follows] 

  
 4 

			
		
	

	    	

  

 IN WITNESS WHEREOF, USA Mobility, Inc., by its duly authorized officer acting in
accordance with a resolution duly adopted by the Compensation Committee of the Board of Directors of USA Mobility, Inc., has executed this Plan for the benefit of employees of USA Mobility Wireless, Inc., and Amcom Software, Inc., on
December 1, 2011, effective as of January 1, 2012. 
  

	
	USA MOBILITY, INC.
	
	  
	Vincent D. Kelly, President & CEO

  
 5 

			
		
	

	    	

  

 Exhibit A 
 Performance Objectives 
 USA Mobility 2012 Short Term Incentive Plan
(STIP) Payout Scale 

 

			$00,000		$00,000		$00,000
	
Consolidated Operating Cash Flow (50%)

	($ in millions)
	  	  	Result	  	Performance	 	Payout
	 	  	$65.807	  	120.0%	 	125.0%
	 Over
	  	$63.065	  	115.0%	 	120.0%
	 Perform
	  	$60.323	  	110.0%	 	115.0%
	 	  	$57.581	  	105.0%	 	107.5%
	 Target
	  	$54.839	  	100.0%	 	100.0%
	 	  	$52.097	  	95.0%	 	92.5%
	 Under
	  	$49.355	  	90.0%	 	85.0%
	 Perform
	  	$46.613	  	85.0%	 	80.0%
	 	  	$43.871	  	80.0%	 	75.0%
	 	  	<$43.871	  	< 80.0%	 	0.0%

 

			$000,000		$000,000		$000,000
	
Consolidated Revenue (20%)

	($ in millions)
	  	  	Result	  	Performance	 	Payout
	 	  	$246.508	  	110.0%	 	125.0%
	 Over
	  	$235.303	  	105.0%	 	115.0%
	 Perform
	  	$229.700	  	102.5%	 	110.0%
	 	  	$226.339	  	101.0%	 	105.0%
	 Target
	  	$224.098	  	100.0%	 	100.0%
	 	  	$221.857	  	99.0%	 	95.0%
	 Under
	  	$218.495	  	97.5%	 	90.0%
	 Perform
	  	$212.893	  	95.0%	 	85.0%
	 	  	$201.688	  	90.0%	 	75.0%
	 	  	<$201.688	  	< 90.0%	 	0.0%

  

 

			$00,0000		$00,0000		$00,0000
	
Operations Bookings (15%)

	($ in millions)
	  	  	Result	 	Performance	 	Payout
	 	  	$***	 	***%	 	***%
	 Over
	  	$***	 	***%	 	***%
	 Perform
	  	$***	 	***%	 	***%
	 	  	$***	 	***%	 	***%
	 Target
	  	$***	 	***%	 	***%
	 	  	$***	 	***%	 	***%
	 Under
	  	$***	 	***%	 	***%
	 Perform
	  	$***	 	***%	 	***%
	 	  	$***	 	***%	 	***%
	 	  	<***	 	<***%	 	***%

 

			$000,000		$000,000		$000,000
	
Paging Revenue (15%)

	($ in millions)
	  	  	Result	 	Performance	 	Payout
	 	  	$***	 	***%	 	***%
	 Over
	  	$***	 	***%	 	***%
	 Perform
	  	$***	 	***%	 	***%
	 	  	$***	 	***%	 	***%
	 Target
	  	$***	 	***%	 	***%
	 	  	$***	 	***%	 	***%
	 Under
	  	$***	 	***%	 	***%
	 Perform
	  	$***	 	***%	 	***%
	 	  	$***	 	***%	 	***%
	 	  	<***	 	<***%	 	***%

 
 

  
 In order for an employee of Wireless
to earn over 100% of their target bonus, Wireless Company OCF must equal or exceed $*** and in order for an employee of Software to earn over 100% of their target bonus, Software Company OCF must equal or exceed $*** 

In order for the CEO of USA Mobility, Inc., to earn more than 100% of his target bonus, Wireless Company OCF must equal or exceed $*** and Software
Company OCF must equal or exceed $***. 
  

	***	Means that certain confidential information has been deleted from this document and filed separately with the Securities and Exchange Commission.Research and Development Agreement

			
	Confidential Treatment Requested	  	Exhibit 10.26

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 

RESEARCH AND DEVELOPMENT AGREEMENT 
 This Research and Development Agreement (the “Agreement”), effective as of November 1, 2011 (the “Effective Date”), is by and between Dexcom, Inc., a Delaware
Corporation having its principal place of business at 6340 Sequence Drive, San Diego, California 92121 (“Dexcom”), and Roche Diagnostics Operations, Inc., a Delaware corporation having its principal place of business at 9115 Hague
Road, Indianapolis, Indiana 46250 (“Roche”). Roche and Dexcom are each referred to herein as a “Party” and collectively as the “Parties”. 

RECITALS 

A. Dexcom is in the business of developing and commercializing continuous glucose monitoring systems, and is preparing to seek and obtain
regulatory approval and to commence marketing a next generation system; 
 B. Roche is currently developing its next generation
diabetes management system; 
 C. Roche and Dexcom desire to create an integrated system using each of the Party’s next
generation system; and 
 D. The Parties desire to enter into this Agreement in order to establish terms between the Parties to
further the development of an integrated system to be marketed in the United States of America. 
 WITNESSETH 

NOW THEREFORE, in consideration of the mutual covenants set forth herein, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 DEFINITIONS 

In addition to other terms defined in this Agreement, capitalized terms used in this Agreement have the following meanings: 

(a) “Affiliate(s)” shall mean a) an organization, which directly or indirectly controls a Party of this Agreement; b) an
organization, which is directly or indirectly controlled by a Party to this Agreement; c) an organization, which is controlled, directly 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 
or indirectly, by the ultimate parent company of a Party. Control as per a) to c) is defined as owning more than fifty percent of the voting stock of a company or having otherwise the power to
govern the financial and the operating policies to appoint the management or to appoint the management of an organization. With respect to Roche the term “Affiliate” shall not include Chugai Pharmaceutical Co. Ltd., 1-1-
Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo, 103-8324, Japan (“Chugai”), unless Roche opts for such inclusion of Chugai by giving written notice to Dexcom. 
 (b) “Accu-Chek System(s)” means Roche’s future generation insulin infusion pump system(s) components of which may include blood glucose monitoring system(s), handheld controller(s)
and other peripheral(s) including but not limited to software. 
 (c) “Applicable Laws” means any and all
applicable common law, statutes, ordinances, rules, regulations, codes, requirements, laws or orders of any agencies, commissions, officials, courts and other governmental and regulatory authorities and instrumentalities of the United States
governing: (i) marketing approval or clearance, testing, investigation, design, manufacture, packaging, labeling, handling, storage, distribution, installation, servicing, marketing, or sale, (ii) recordkeeping and reporting obligations,
(iii) recalls, or (iv) similar regulatory matters, with respect to the Services provided and/or the products to which the Services relate. Applicable Laws shall include, without limitation, (a) if the Services involve the design,
manufacture, packaging, labeling, storage, installation, or servicing of a medical device or accessory that is suitable for use or capable of functioning (whether or not it is packaged, labeled, or sterilized), current good manufacturing practices
as specified in the FDA’s Quality System Regulation at 21 CFR Part 820, including but not limited to the Design Controls requirements at 21 CFR Part 820, Subpart C, (b) the Clinical Laboratories Improvement Act and regulations promulgated
thereunder, 42 U.S.C. 263a and 42 CFR Part 493, and (c) any similar regulatory requirements, as such regulatory requirements are in effect at the time the Services are provided, and as such regulations and similar regulatory requirements are
interpreted at the time. 
 (d) “CGM Technologies” shall mean Dexcom’s continuous glucose monitoring
platform that senses and analyzes interstitial glucose levels, which includes the G5 System, and its predecessor and successor systems. 
 (e) “Claims” has the meaning set forth in Section 9.1.1 of this Agreement. 
 (f) “Confidential Information” means any and all of the following information of Roche and/or its Affiliates or Dexcom and/or its Affiliates (each, a “Disclosing Party”)
that may be hereafter disclosed in any form, whether in writing, orally (if orally or by observation, the Disclosing Party must memorialize such information in writing within thirty (30) days of disclosure to maintain its confidential nature),
electronically or otherwise and marked “Confidential” (the “Receiving Party”): a) all information that is a trade secret under applicable trade secret law or other legal requirement; b) all information concerning product
specifications, data, know-how, formulae, compositions, processes, designs, sketches, photographs, graphs, drawings, samples, inventions and ideas, past, current and planned manufacturing or distribution methods and processes, customer lists, health
care professional lists, current and anticipated 

  
 Page
2 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 
customer requirements, price lists, market studies, business plans, hardware and software; c) all information concerning the business and affairs of the Disclosing Party (and/or its Affiliates)
(which includes financial statements, financial projections and budgets, sales, strategic plans, marketing and advertising plans, publications, client and customer lists and files, contracts), and all information obtained from review of the
Disclosing Party’s documents or property or discussions with the Disclosing Party; and d) all notes, analyses, compilations, studies, summaries and other material prepared by the Receiving Party to the extent containing any information included
in the foregoing. Provided, however, that “Confidential Information” shall not include information that the Receiving Party can demonstrate by competent proof: (i) was generally available to the public at the time of receipt from the
Disclosing Party, or thereafter becomes generally available to the public other than through a breach of this Agreement by the Receiving Party; (ii) is or has been independently developed or conceived by the Receiving Party without use of the
Disclosing Party’s confidential information; (iii) is or has been made known or disclosed to the Receiving Party without breach of any obligation of confidentiality such third party may have to the Disclosing Party; or (iv) is known
to the Receiving Party prior to disclosure by the Disclosing Party and is not otherwise subject to any obligations of confidentiality. 
 (g) “Development Plan” has the meaning set forth in Section 13.4 of this Agreement. 
 (h) “Dexcom Indemnitees” has the meaning set forth in Section 9.1.2 of this Agreement. 
 (i) “Dexcom IP” shall mean any software or other Intellectual Property (i) owned or licensed by Dexcom or for which Dexcom has the right to use or otherwise exploit as of, or prior
to, the Effective Date (“Dexcom Background IP”), or (ii) independently made, conceived or developed solely by Dexcom, its employees, or persons acting on behalf of Dexcom, regardless of whether such activity is performed
outside of this Agreement (“Dexcom Solely Developed IP”). 
 (j) “Dexcom
Trademarks” shall mean DexCom® and such other Dexcom trademarks specifically related to the G5 System
as Dexcom may designate in writing to Roche from time to time. 
 (k) “Display Specifications” shall mean the
(i) wireless communication protocol (and any improvements thereto that are delivered by Dexcom to Roche during the Term) owned by, developed by or licensed to Dexcom and licensed to Roche hereunder, as well as, (ii) the User Interface (and
any improvements thereto that are delivered by Dexcom to Roche during the Term) owned and developed by Dexcom and licensed to Roche and to be set forth in an exhibit to the Development Plan. 

(l) “FDA” means the United States Food and Drug Administration. 

(m) “G5 System” means Dexcom’s next generation continuous glucose monitoring system and those future enhancements
or improvements thereto that does not require Dexcom to file a new PMA. 

  
 Page
3 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 (n) “Handheld” means the display device and controller that is part of
the Accu-Chek Systems and which contains the Display Specifications. 
 (o) “Indemnified Parties” has the
meaning set forth in Section 9.2 of this Agreement. 
 (p) “Indemnifying Party” has the meaning set forth
in Section 9.2 of this Agreement. 
 (q) “Initial Statement of Work” has the meaning set forth in
Section 1.1 of this Agreement. 
 (r) “Initial Term” has the meaning set forth in Section 8.1 of this
Agreement. 
 (s) “Integrated System” shall mean the Accu-Chek Systems that are also capable of receiving and
displaying continuous glucose monitoring data and to be marketed in the Territory. The Integrated System is comprised of: (1) an Accu-Chek System, (2) G5 System and (3) the Display Specifications. 

(t) “Integrated System Infringement Action” has the meaning set forth in Section 9.1.3 of this Agreement.

 (u) “Intellectual Property” means, collectively, patents, copyrights, trademarks, trade names, trade
secrets, and other proprietary and intellectual property rights. 
 (v) “Invention” means any idea, design,
concept, technique, process, invention, discovery or improvement, whether or not patentable and which is conceived and or made by one or more employees or other persons acting on behalf of either Party. 

(w) “Joint Invention” shall mean, all Inventions (including all jointly made derivations and improvements), whether or
not patented, that are conceived, reduced to practice, developed, made or produced jointly by Dexcom Personnel and Roche Personnel (as determined by US Patent Law) during the Term. 

(x) “Milestone Payments” has the meaning set forth in Section 2.1 of this Agreement. 

(y) “Personnel” means, with respect to each Party, such Party’s employees and independent contractors. 

(z) “PMA” means pre-market approval pursuant to 21 CFR Part 814. 

(aa) “Project Leader” has the meaning set forth in Section 3.1 of this Agreement. 

  
 Page
4 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 (bb) “Receipt Date” has the meaning set forth in Section 2.2 of
this Agreement. 
 (cc) “Requirements” has the meaning set forth in Section 13.1 of the Agreement.

 (dd) “Roche Indemnitees” has the meaning set forth in Section 9.1.1 of this Agreement. 

(ee) “Roche IP” shall mean any software or other Intellectual Property (i) owned or licensed by Roche or for which
Roche has the right to use or otherwise exploit as of, or prior to, the Effective Date (“Roche Background IP”), or (ii) independently made, conceived or developed solely by Roche, its employees, or persons acting on behalf of
Roche, regardless of whether such activity is performed outside of this Agreement (“Roche Solely Developed IP”). 
 (ff) “SCAR” has the meaning set forth in Section 4.2. 
 (gg)
“SCAR Response” has the meaning set forth in Section 4.2. 
 (hh) “Sensor” means a
disposable continuous glucose monitoring electrode sensor that is a component of the G5 System, and was designed, developed, and owned by Dexcom to (i) penetrate the patient’s skin to come into contact with the patient’s interstitial
fluid (ii) measure interstitial fluid glucose levels, and (iii) be connected to a Transmitter to communicate the interstitial fluid glucose value as measured by the Sensor to the Transmitter. 

(ii) “Service Fees” has the meaning set forth in Section 2.1 of this Agreement. 

(jj) “Services” has the meaning set forth in Section 1.1 of this Agreement. 

(kk) “Statement of Work” has the meaning set forth in Section 1.1 of this Agreement. 

(ll) “Steering Committee” has the meaning set forth in Section 3.7 of this Agreement. 

(mm) “Term” has the meaning set forth in Section 8.1 of this Agreement. 

(nn) “Territory” shall mean the United States of America and all of its territories. 

(oo) “Transmitter” means a radio frequency transmitter that is a component of the G5 System, and is located on or near
the skin surface and connected to the Sensor, which receives and transmits the representative glucose value measured by the Sensor to the Accu-Chek Systems. 
 (pp) “User Interface” shall mean any and all technology necessary to incorporate the graphical display and audio features of continuous glucose monitoring capabilities into the Accu-Chek
Systems including, but not be limited to, the graphical display of and audio features for use cases, alerts, alarms, error messages, battery management, etc.; provided, however, the term ‘User Interface” shall not include any algorithms,
source code or other technologies that process sensor data. 

  
 Page
5 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 (qq) “Work Product” means all Services prepared and delivered by Dexcom
or its Personnel pursuant to any Statement of Work. Work Product shall include but not be limited to the Development Plan and any deliverables thereunder, the Regulatory Plan and any deliverables thereunder and all validation, verification and
calibration data for the Integrated System. Work Product shall not include Dexcom IP, Roche IP, Joint Invention, the G5 System (including all specifications, designs, algorithms, data, clinical trial protocols and other materials generated by
Dexcom for the G5 System) the Display Specifications (including specifications and designs), and/or such other items as may be specifically excluded in any Statement of Work. 

 

	 	1.	Services 

 1.1
Statements of Work. Each Party during the Term of this Agreement shall provide those services required to be performed by it (the “Services”) as set forth in a written statement of work executed by Roche and Dexcom (a
“Statement of Work”) and in this Agreement; provided however that no Party shall have any obligation to perform, purchase, provide or accept any Services unless and until a Statement of Work is executed hereunder and a purchase
order is issued. Attached as Exhibit A to this Agreement is the initial Statement of Work for both Parties (the “Initial Statement of Work”). The Parties may amend any Statement of Work, including the Initial Statement of Work, at
any time by mutual written agreement. 
 1.2 Changes to Statements of Work. Changes to a Statement of Work may be
provided through recommendation(s) by the Steering Committee as described in Section 3.7. Upon receipt of such changes to the Statement of Work, the Parties shall execute an amendment to the applicable Statement of Work reflecting such changes.

 1.3 Facilities. Dexcom shall provide Services required to be performed by it at the facility or facilities identified
in the applicable Statement of Work. 
 1.4 Materials for Services. Subject to Roche’s obligation under
Section 2.1 of this Agreement to reimburse Dexcom for certain expenses, each Party shall provide the necessary materials, including but not limited to, prototypes, software, source codes, manuals, and documents, at its own expense to complete
such Services in the applicable Statement of Work. 
 1.5 Cooperation. The performance of all Services hereunder shall be
coordinated by the Project Leaders (as defined in Section 3.1). The Parties agree that the successful carrying out of any Services is largely dependent upon the cooperation and the regular exchange of information between the Parties. The
Parties shall facilitate the Services provided hereunder through the regular exchange of information. Each Party shall inform the other Party without undue delay about any delays in the Services or the achievement of any milestones under any
Statement of Work. 

  
 Page 6 of
30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

	 	2.	Fees and Payment Terms 

2.1 Fees. Subject to Section 2.2, Roche shall pay Dexcom the fees set forth in the applicable Statement of Work in accordance
with the terms set forth therein (the “Service Fees”) and the milestone payments set forth in the Initial Statement of Work in accordance with the terms set forth therein (the “Milestone Payments”). In addition to
the Service Fees, Roche may be required to reimburse Dexcom for those expenses set forth in the Statement of Work in accordance with the terms set forth therein. Roche shall not be obligated to reimburse Dexcom for any expenses not set forth in a
Statement of Work, unless such expenses are pre-approved by Roche. The Service Fees, Milestone Payments and any expenses reimbursed by Roche shall constitute Dexcom’s complete compensation for the performance of the Services required to be
performed by it and the licenses granted in Section 6.5. Dexcom shall have no obligation to compensate Roche for, or reimburse Roche for any expenses incurred in connection with, Roche’s performance of its obligations under this Agreement
or any Services required to be performed by it. The Service Fees shall not exceed $1,000,000 under this Agreement and all Statements of Work, collectively, unless the Parties otherwise agree in writing. 

2.2 Payment Terms. Unless otherwise specified in a particular Statement of Work, Dexcom shall issue within fifteen
(15) calendar days of the end of each calendar month during the Term of this Agreement, an invoice for the Services it performed in such month. Roche shall pay Dexcom all undisputed amounts for such Services within forty-five (45) calendar
days after Roche’s receipt of a complete invoice therefor (the “Receipt Date”). 
 2.3 Taxes. To
the extent that Services supplied hereunder are subject to any sales, use, value added or any other taxes, payment of said taxes, if any, is Dexcom’s responsibility and said taxes are included in the Service Fees. Dexcom shall be liable for any
and all taxes on any and all income it receives from Roche under any agreement and shall make appropriate filings with the taxing authorities for all taxes and payments for person(s) employed by Dexcom. 

 

	 	3.	Personnel 

 3.1
Project Leader. Roche and Dexcom shall each designate a “Project Leader” for each Statement of Work who shall be the principal point of contact for all matters relating to such Statement of Work. The Project Leader designated
by a Party for a Statement of Work may be changed by written notice to the other Party to such Statement of Work. 
 3.2
Employees; Independent Contractors. Each Party shall provide all of the Services through its Personnel. 
 3.3
Qualifications. Each Party shall ensure that all Personnel providing Services hereunder have the necessary and appropriate education, background, training, and experience to provide the Services requested and to perform such Services in
compliance with this Agreement, including any special training required pursuant to the applicable Statement of Work. 

  
 Page 7 of
30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 3.4 Key Personnel. Each Statement of Work may designate certain individuals as
“Key Personnel” for the Services to be performed by each Party, and the Parties thereto subsequently may agree in writing that additional individuals are Key Personnel for the Services. 

3.5 Performance of Personnel. If Roche becomes dissatisfied with the performance of any Personnel providing Services, Roche may
notify Dexcom of the details of the unsatisfactory performance, and the Parties shall cooperate to remedy the problem as soon as reasonably possible. In the event any Personnel are replaced, the replacement Personnel’s rate shall be no higher
than the rate of the Personnel that was replaced, nor shall Roche be required to pay for time spent by replacement Personnel becoming familiar with the Services or training to perform the Services under this Agreement. 

3.6 Responsibility for Personnel. Each Party assumes full responsibility for the actions and omissions of all its Personnel
performing Services hereunder, either at Dexcom’s or Roche’s facility, and shall be solely responsible for their supervision, daily direction and control, payment of salary (including withholding of income taxes and social security),
workmen’s compensation and occupational insurance as required by law, comprehensive public liability insurance, compensation, disability benefits and the like. Under no circumstances will either Party’s Personnel be considered employees or
agents of the other Party. Each Party agrees that, while its Personnel are on the other Party’s premises, they will conform to all of the other Party’s work rules, safety regulations and its standard practices governing behavior of its own
employees. Each Party shall be liable for all acts and omissions of any independent contractors that perform Services to the same extent as if they were the acts and omissions of employees of that Party. 

3.7 Steering Committee. Roche and Dexcom will establish a steering committee (the “Steering Committee”) to
coordinate and oversee the overall implementation of this Agreement, the Development Plan and the Regulatory Plan (as defined in Section 13.4) and to approve the final specifications and designs of the Integrated System, which approval will not
be unreasonably withheld. The Steering Committee will consist of an equal number of representatives of each Party, and all decisions of the Steering Committee will be by unanimous consent. At a minimum, the Steering Committee shall be
comprised of senior R&D management from each Party. Each Project Leader shall provide regular reports and identify any issues to the Steering Committee. In the event the Steering Committee is unable to reach unanimous consent on any
material issue, the Steering Committee will not take action on such issue without the prior approval of the President of Dexcom and the Head of Diabetes Care at Roche. Notwithstanding the foregoing, the Parties shall further determine additional
roles, responsibilities and functions of the Steering Committee. 
  

	 	4.	Quality 

 4.1 Service
Quality; Warranty. Dexcom expressly warrants and covenants all Services furnished under this Agreement shall be provided in a workmanlike manner and in accordance with the generally accepted practices in the applicable Service industry and all
terms and conditions of this Agreement and the Statement of Work, including Section 13.1 hereof 

  
 Page 8 of
30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 4.2 Dexcom Corrective Action Request. If, during the Term of this Agreement,
Roche reasonably identifies an issue that may affect the quality of the Services performed by Dexcom, Work Products or Dexcom’s quality control processes or procedures or compliance with this Agreement, Roche may at its sole discretion, issue
to Dexcom a Supplier Correction Action Request (each a “SCAR”). Within fifteen (15) calendar days after the issue date of the SCAR, Dexcom shall deliver to Roche a detailed response to the SCAR (a “SCAR
Response”). If final closure and verification on the issue or issues identified in the SCAR cannot be achieved within fifteen (15) calendar days of Dexcom’s receipt of the SCAR, as part of the SCAR Response, Dexcom shall submit to
Roche an action plan detailing its proposed plan to correct the issues identified in the SCAR. Roche shall have the right to review and propose revisions to any such action plans, and all such action plans are subject to Roche’s written
approval. Following Roche’s approval and Dexcom’s initial implementation of the corrective action plan, Dexcom shall provide bi-weekly status reports to Roche until final verification of the corrective action is accomplished and Roche
accepts the corrective action by written notice to Dexcom. In the event that Dexcom breaches its obligations under this Section 4.2, Roche’s sole remedy shall be to terminate this Agreement. 

4.3 License, Accreditation and Certifications. Each Party shall obtain and maintain, at its expense, all licenses, accreditations
and certifications necessary for it to provide Services. 
  

	 	5.	Delivery and Acceptance 

5.1 Delivery. Each Party shall perform the Services required to be performed by it upon the timeframes set forth in the applicable
Statement of Work. In the event that a Party cannot meet such schedule, and provided that such delay is beyond the reasonable control of that Party, the Parties will mutually agree on a revised schedule for the performance of such work. 

5.2 Prototypes. During the development of the Integrated System, Roche and Dexcom shall deliver prototypes of the Accu-Chek
Systems and the G5 System respectively, in accordance with the schedule specified in the Statement of Work, as required for testing and evaluation purposes. In the event that such prototypes fail to meet the mutually agreed upon criteria, the
responsible party shall modify such prototypes and deliver a new prototype that conforms to such criteria. If after Dexcom finalizes the specifications and design for the G5 System, Dexcom learns of or discovers any material defects that affect the
safety or efficacy of G5 System, it will notify Roche and use commercially reasonable efforts to remedy any such defects. If Dexcom learns of or discovers any material defects that affect the safety or efficacy of the Display Specifications, it will
notify Roche and use commercially reasonable efforts to remedy any such defects. If after Roche finalizes the specifications and design for the Accu-Chek Systems, Roche learns of or discovers any material defects that affect the safety or efficacy
of Accu-Chek Systems, it will notify Dexcom and use commercially reasonable efforts to remedy any such defects to the Accu-Chek System or improvements to the Display Specifications. If Roche notifies Dexcom that the Display Specifications affects
the safety or efficacy of the Accu-Chek System, the Parties shall use commercially reasonable efforts to remedy any such defects. 

  
 Page 9 of
30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

	 	6.	Ownership Rights and Licenses 

 6.1 Original Work. All Work Products shall be the original work of Dexcom and its Personnel, and all Work Product shall be owned by Roche. Neither Party shall disclose to the other Party or induce
the other Party to use the trade secrets of others. 
 6.2 Joint Inventions. 

(a) [*****] 

(b) [*****] 

6.3 Works Made for Hire. Dexcom agrees that all Work Products that are works of authorship shall be deemed “works made for
hire” within the meaning of the copyright laws of the United States and Roche shall own all right, title and interest in and to such Work Product, including the entire copyright in the Work Product. 

6.4 Assignment of Rights. Subject to Section 6.5, Dexcom further agrees that to the extent any Work Product or part thereof
is not a “work made for hire,” Dexcom agrees to assign, and hereby assigns, to Roche ownership of all right, title and interest in and to such Work Product or part thereof, and agrees that Roche shall be the sole and exclusive owner of all
right, title and interest in and to such Work Product, including without limitation, all patent, copyright, trademark, trade secret and other proprietary rights therein that may be secured in any place under any laws now or hereinafter in effect.
Dexcom agrees to execute all assignments and other instruments and documents necessary for Roche to perfect its ownership of its rights in the Work Product. Except as set forth in Section 6.2(b), no license in or to any Work Products is granted
to Dexcom either expressly or by implication, estoppel or otherwise. 

  
 Page
10 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 6.5 Grant of Licenses to Roche. 

(a) [*****] 

(b) [*****] 

(c) [*****] 

(d) [*****] 

(e) [*****] 

(f) In consideration of the licenses granted by this Section 6.5, Roche shall only pay to Dexcom (A) the Milestone Payments
described in Section 2.1 hereof for access to the Display Specifications and (B) a payment of $100 for each sale of the Accu-Chek System which has been approved by the FDA with the G5 System, which such payment shall be set out in the
commercialization agreement contemplated hereby. 
 (g) [*****] 

  
 Page
11 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 (h) [*****] 
 6.6 Roche Intellectual Property. Subject to Section 6.2(b), and unless specifically granted otherwise in a Statement of Work, nothing contained in this Agreement shall be construed to
grant Dexcom a license to or in any way give ownership to any Roche IP, except that Dexcom shall have access to and the right to use such Roche IP during the Term as required for Dexcom to fulfill, and solely for the purpose of fulfilling, its
contractual obligations herein.
 6.7 Prosecution and Maintenance of Patents: 

(a) Roche IP and Joint Inventions: With regard to all Roche IP and any Joint Inventions, Roche shall control, at its sole discretion and
expense, the preparation, prosecution and maintenance of all patents and patent applications. 
 (b) Dexcom IP: With regard to
all Dexcom IP, Dexcom shall control, at its sole discretion and expense, the preparation, prosecution and maintenance of all patents and patent applications. 
 6.8 Enforcement. If either Party has knowledge of any infringement claim or other claim relating to any Work Products, Joint Inventions, the G5 System, Display Specifications, the Accu-Chek
Systems, such Party shall promptly inform the other Party in writing of such claim. 
  

	 	7.	Additional Representation and Warranties. 

 7.1 Authorization. Both Parties have the requisite corporate power and authority (a) to execute and deliver this Agreement, (b) to perform its obligations hereunder, and (c) to grant
the rights described in this Agreement. This Agreement has been duly authorized, executed, and delivered by both Parties and constitutes the legal, valid and binding obligation of each Party 

  
 Page
12 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 
enforceable in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency, or other similar laws relating to or affecting generally the enforcement of
creditors rights or by general equitable principles. 
 7.2 No Conflict. The execution and delivery of this Agreement and
the incurrence of the obligations and consummation of the transactions herein contemplated will not conflict with, or constitute a breach of or default under, the certificate of incorporation or by-laws of either Party or any material contract,
indenture, mortgage, loan agreement, or lease to which either Party is party or by which it may be bound, or any law, administrative regulations, or court decree. 
 7.3 Consents. No consent, approval, authorization, order, registration, or qualification of or with any person, entity, court or any regulatory authority or other governmental agency or body is
required for the execution and delivery of this Agreement by either Party or for the legality, validity or enforceability of the transactions contemplated by this Agreement. 
 7.4 Infringement and Adverse Action. Dexcom represents and warrants, to the best of its knowledge, that as of the date of this Agreement, Roche’s use of the prototype components of the G5
System supplied by Dexcom to Roche, the Display Specifications, and the Work Product, each as used solely for the development of the Integrated System, does not infringe any patent, copyright, trade secret, or other proprietary right of any third
party. Roche represents and warrants, to the best of its knowledge, that as of the date of this Agreement, use of the Accu-Chek System, as used solely for the development of the Integrated System, does not infringe any patent, copyright, trade
secret, or other proprietary right of any third party. 
 7.5 Invention Rights. Each Party represents and warrants that
all of its Personnel have assigned, or will assign, all of their respective rights in or to any Inventions to such Party and that it has, or will have, sufficient rights and title to grant the rights and licenses to the other Party specifically
contemplated by this Agreement. 
  

	 	8.	Term and Termination 

8.1 Term of Agreement. The “Initial Term” of this Agreement shall begin on the Effective Date and shall, unless
earlier terminated pursuant to Section 8.3 below, continue in full force and effect through December 31, 2014. Subsequent to the Initial Term, this Agreement shall be automatically renewed thereafter for consecutive one-year periods unless
a Party (a) provides the other Party written notice of its intent not to renew the Agreement ninety (90) days prior to the expiration of the then current Term, or (b) otherwise terminates the Agreement in accordance with
Section 8.3. For purposes of this Agreement, the Initial Term and any renewal periods thereafter shall be referred to herein as the “Term.” 
 8.2 Term of Statements of Work. The term of each Statement of Work shall commence on the date set forth in the Statement of Work and, unless earlier terminated pursuant to Section 8.3 below,
continue in full force and effect for the term set forth therein. 

  
 Page
13 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 8.3 Termination. 

8.3.1 Termination for Cause. 
 8.3.1.1 Material Breach. Either Party shall have the right to terminate this Agreement and/or any affected Statement(s) of Work upon immediate written notice if the other Party is in material
breach or material default of any of its representations, warranties, covenants, or other obligations set forth in this Agreement or such Statement of Work and such Party fails to cure such breach or default within thirty (30) calendar days
following receipt of written notice of such breach. Except as otherwise provided in this Agreement, in the event of such termination, the non-breaching Party shall be entitled to seek all available remedies at law or in equity in addition to
exercising its right to terminate. 
 8.3.1.2 Insolvency. Either Party may, at its sole option, immediately terminate
this Agreement and/or any Statement(s) of Work upon written notice, but without prior advance notice, to the other Party in the event that (A) the other Party is or becomes insolvent or is declared bankrupt by a court of competent jurisdiction;
(B) a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by such other Party; (C) an involuntary petition for bankruptcy is filed in any court of competent jurisdiction against such other Party; (D) a
receiver or trustee is appointed for such other Party; or (E) this Agreement is assigned by such other Party for the benefit of creditors. For purposes of this Agreement, a Party shall be deemed to be “insolvent” when such Party has
ceased to pay its debts in the ordinary course of business, cannot pay its debts as they become due, or is insolvent within the meaning of the federal bankruptcy law. 
 8.3.2 Termination Without Cause. Roche may terminate this Agreement or any Statement(s) of Work for any reason or no reason upon written notice to Dexcom at least thirty (30) calendar days in
advance of the effective date of the termination. 
 8.4 Effect of Termination. Upon the expiration or termination of a
Statement of Work, each Party shall cease providing Services under that Statement of Work and Dexcom shall promptly deliver to Roche all Work Products, whether completed or work in progress. Provided the Statement of Work was not terminated as the
result of a breach by Dexcom, Dexcom may invoice Roche, and in such event Roche shall pay Dexcom in accordance with Section 2.2, for any Services satisfactorily performed and expenses properly incurred prior to notice of termination.
Notwithstanding the foregoing, if Roche elects to terminate this Agreement pursuant to Section 8.3.2, or if Dexcom elects to terminate this Agreement pursuant to Sections 8.3.1.1 or 8.3.1.2, then Dexcom shall have no obligation to repay any
Milestone Payments previously paid to it by Roche as of the date of expiration or termination. The termination of one Statement of Work shall not affect this Agreement or any other Statement of Work and notwithstanding, the termination or expiration
of this Agreement, the terms and conditions of this Agreement shall continue in effect with respect to each Statement of Work until the expiration or termination of such Statement of Work. In case of termination of this Agreement, the Steering
Committee shall determine whether Statement of Works that have been signed prior to this termination date shall be performed in full, also after termination of this Agreement. If the Steering Committee determines so, said Statement of Works to
be completed shall be carried out analogous to the 

  
 Page
14 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 
rules and stipulations under the then terminated Agreement. In case of a termination of this Agreement any payments by Roche are only due for such works rendered by Dexcom until the moment of
termination, except for works carried out under Statement of Works to be continued according to the Steering Committee’s decision. 
 8.5 Survivability. The rights and obligations of Sections 4.1, 6.1, 6.2, 6.3, 6.4, 6.5(b), 6.5(c), 6.5 (d), 6.6, 6.7, 8.4, 8.5, 15.1, 15.2 (only with respect to Dexcom’s obligation to
maintain Records under such Section) and 15.3 and Articles 9, 12 and 16 shall survive any termination of this Agreement and shall bind the Parties and their legal representatives, successors, and assigns. 

 

	 	9.	Indemnification 

 9.1
Infringement Indemnification. 
 9.1.1 By Dexcom. Dexcom shall defend, indemnify and hold harmless Roche and its
Affiliates, and each of their respective directors, officers, employees, and agents, and their respective successors and permitted assigns (collectively, the “Roche Indemnitees”) from and against any and all claims, actions, causes
of action, liabilities, losses, costs, expenses, or damages, including reasonable attorneys’ fees (collectively, “Claims”) against any of (a) the Display Specifications, (b) G5 System, (c) any Work Product or the
exploitation or use of such Work Product by the Roche Indemnitees, or (d) any process created or utilized by Dexcom in connection with the performance of Services by Dexcom, for infringement or misappropriation of any patent, copyright, trade
secret or other intellectual property or proprietary right of another person or entity. 
 9.1.2 By Roche. Roche shall defend,
indemnify and hold harmless Dexcom and its Affiliates, and each of their respective directors, officers, employees, and agents, and their respective successors and permitted assigns (collectively, the “Dexcom Indemnitees”) from and
against any and all Claims against either of (a) the Accu-Chek System or (b) any process created or utilized by Roche in connection with the performance of Services by Roche, or the exploitation or use thereof by the Dexcom Indemnitees,
for infringement or misappropriation of any patent, copyright, trade secret or other intellectual property or proprietary right of another person or entity. 
 9.1.3 If the development, manufacture, import, sale or use of the Integrated System results in a Claim against Roche and/or Dexcom alleging infringement of a claim of a patent or alleges infringement or
misappropriation of some other intellectual property right of a third party and neither of Dexcom or Roche is entitled to indemnification pursuant to Sections 9.1.1 and 9.1.2 (“Integrated System Infringement Action”), such Party
will promptly notify the other Party in writing. The Parties will cooperate and share equally costs related to the defense of any Integrated System Infringement Action. The Parties will consult prior to entering any settlement agreement concerning
any Integrated System Infringement Action and, in the event a Party desires that the other Party not accept a proposed settlement agreement, the Parties will negotiate in good faith regarding alternatives to accepting the proposed settlement
agreement. 

  
 Page
15 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 9.2 General Indemnification. Each Party (the “Indemnifying
Party”) shall protect, defend, indemnify, and hold the other Party, its Affiliates and each of their respective directors, officers, employees, and agents, and their respective successors and permitted assigns (collectively, the
“Indemnified Parties”) harmless from and against any and all claims, actions, causes of action, liabilities, losses, costs, expenses, or damages, including reasonable attorneys’ fees, incurred by the Indemnified Parties which
directly or indirectly arise out of or relate to (i) the breach by the Indemnifying Party of any of its representations, warranties, covenants, agreements, or obligations set forth in this Agreement or any Statement of Work, (ii) physical
injury (including death) and/or property damage actually or allegedly caused by the Indemnifying Party’s products, parts, or services and that is not the result of the other Party’s products, parts or services, or (iii) the
negligence, recklessness, or willful misconduct of the Indemnifying Party in connection with its performance of its obligations set forth in this Agreement or any Statement of Work. 

9.3 Notice of Claims. Any Indemnified Party claiming indemnification hereunder shall give to the Indemnifying Party
(i) prompt written notice of any third-party claim(s) made against the Indemnified Party for which the Indemnified Party knows or reasonably should know that the Indemnifying Party may be liable hereunder, and (ii) the opportunity to
defend, negotiate, and settle such third-party claim(s). The Indemnified Party shall provide the Indemnifying Party with all information in its possession reasonably related to such third-party claim, all authority, and all assistance necessary to
enable the Indemnifying Party to carry on the defense of such suit; provided, however, the Indemnified Party reserves the right to retain its own counsel to defend itself in such suit. Notwithstanding the foregoing, the Indemnified
Party shall not be bound by any settlement made without its prior written consent. 
 9.4 Right of Off-Set. To the extent
Roche has incurred expenses in connection with a Claim for which it is entitled to indemnification pursuant to Section 9.1.1 or 9.2 of this Agreement and/or the Co-Promotion and Distribution Agreement between Dexcom, Inc. and Roche Insulin
Delivery Systems, Inc., effective as of September 22, 2011, and Dexcom has not reimbursed such expenses, Roche shall have the right to immediately stop paying any Service Fees and Milestone Payments due to Dexcom under this Agreement or an
applicable Statement of Work until Dexcom has fully indemnified the Roche Indemnitees. 
 9.5 LIMITATION OF LIABILITIES.
NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT EXCEPT WITH RESPECT TO INFRINGEMENT CLAIMS REQUIRED TO BE INDEMNIFIED PURSUANT TO SECTION 9.1 AND THIRD PARTY CLAIMS REQUIRED TO BE INDEMNIFIED PURSUANT TO SECTION 9.2 ABOVE,
OR ANY CLAIM ARISING OUT OF A BREACH OF CONFIDENTIALITY, NEITHER PARTY SHALL BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT OR PUNITIVE DAMAGES WHETHER ARISING OUT OF SAID PARTY’S PERFORMANCE OR NON-PERFORMANCE OF THIS
AGREEMENT, TORT (INCLUDING NEGLIGENCE), WARRANTY, OR OTHERWISE, EVEN IF THE EXCLUSIVE REMEDIES PROVIDED HEREIN FAIL OF THEIR ESSENTIAL PURPOSE AND EVEN IF A PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

  
 Page
16 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

	 	10.	Risk Management 

 10.1
Insurance Requirements. 
 10.1.1 Amounts and Types. During the Term of this Agreement, each Party shall maintain
in full force and effect, at its own expense, insurance coverage by reputable insurers, as set forth below: 
 10.1.1.1
Worker’s Compensation. Worker’s compensation insurance as required by law or regulation. Where permitted by law, such policies shall contain waivers of the insurer’s subrogation rights against the other Party. 

10.1.1.2 Employer’s Liability Insurance. Employer’s liability insurance in amounts not less than $100,000 per accident
for bodily injury by accident, $500,000 policy limit by disease, and $100,000 per employee for bodily injury by disease. 

10.1.1.3 Commercial General Liability. Commercial General Liability insurance with minimum combined per occurrence limits for
bodily injury and property damage of $1,000,000. Commercial General Liability coverage shall also include contractual liability with a minimum of $2,000,000. Each Party is to be named as an additional insured on the other Party’s General
Liability policy. 
 10.1.2 Liability. Nothing contained in this Section 10.1 shall be deemed in any way to either
limit or increase the liability of either Party or their insurers under this Agreement. Notwithstanding anything to the contrary contained herein, each Party’s and its insurers’ liability and obligations to the other shall be limited to
coverage for claims for which it is liable pursuant to this Agreement. 
  

	 	11.	[INTENTIONALLY OMITTED] 

  

	 	12.	Confidentiality 

 12.1
Disclosure; Standard of Care. Both Dexcom and Roche shall retain in confidence all Confidential Information received from the other prior to or during the term of this Agreement and will not, at any time during the term of this Agreement or
after termination hereof, in any fashion, form or manner, either directly or indirectly, copy, reproduce, sell, assign, license, market, transfer, give, or otherwise disclose, divulge, release, or use for any purpose (other than in furtherance of
the respective obligations and covenants contained in this Agreement) any Confidential Information received from the other Party or an Affiliate of the other Party. Each Party and its Affiliates will protect the other Party’s and its
Affiliates’ Confidential Information from unauthorized dissemination and use with the same degree of care that each such Party uses to protect and safeguard its own like information, but not less than the degree of care that would be exercised
by a prudent person given the sensitivity and strategic value of such Confidential Information. Each Party furthermore agrees to not use any Confidential Information disclosed by the other Party or generated hereunder for any purpose other than the
activities agreed to be performed by the Parties hereunder, and to restrict access to 

  
 Page
17 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 
such of its employees as are entrusted to carry out such activities. Such information may, however, be disclosed to the extent required to under applicable laws or regulations or an order by a
court or other regulatory body having competent jurisdiction; provided, however, that except where legally impermissible, the Party required to disclose the Confidential Information shall give the other Party reasonable advance notice of such
disclosure requirement (which shall include a copy of any applicable subpoena or order) and shall afford such Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required disclosure. In the event of any such
required disclosure, the Party obligated to disclose shall only disclose that portion of the Confidential Information of the other Party that it is legally required to disclose. 

12.2 Return of Confidential Information. Each Party agrees not to make any copies in whole or part of Confidential Information of
the other Party for any purpose other than the purposes set forth and agreed to by the Parties hereunder. At the termination or expiration of this Agreement, each Party, upon request by the disclosing Party, shall return all Confidential Information
received from the disclosing Party except as provided in Section 6.5, including any copies thereof, and provide the disclosing Party with a certification that all Confidential Information has either been returned or destroyed; provided,
however, that subject to the terms and conditions of this Agreement, including without limitation, this Article 12, the receiving Party may retain one (1) copy of each item of Confidential Information in its legal department (or with its
outside legal counsel in the case of Dexcom) for use only in monitoring its compliance with obligations here undertaken. 
 12.3
Trade Secret Laws. The confidentiality provisions of this Agreement are in addition to and not in lieu of any protection that either Party may have under applicable trade secret laws relating to the protection of Intellectual Property.

 12.4 Press Releases. Except as may be required by any rules and regulations promulgated by the Securities and Exchange
Commission, or any national securities exchange on which either Party’s securities are traded, Roche and Dexcom shall not issue any press release or public announcement with respect to this Agreement without the prior, written consent of the
other Party as to the form and content of such release. 
  

	 	13.	Regulatory and Related Matters. 

 13.1 Compliance with Laws and Related Requirements. 
 13.1.1
Compliance. Dexcom and Roche shall ensure that all Services are provided by it in accordance with, and shall conform to, (i) all Applicable Laws, (ii) any additional regulatory provisions, operating procedures, quality requirements
and other standards set forth in the applicable Statement of Work, regardless of whether such requirements are mandatory under Applicable Laws, and (iii) both Parties’ internal standard operating procedures and quality requirements
(collectively, the “Requirements”), and shall document the same. Each Party shall notify the other Party promptly if it becomes aware of any non-compliance by it with any of the Requirements and shall take all appropriate action
necessary to promptly correct such non-compliance and fully comply with all of the Requirements. Dexcom and Roche shall document all non-compliance and any steps Dexcom and Roche takes to correct such non-compliance. 

  
 Page
18 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 13.2 Government Audits and Notification of Findings. If, during the Term of this
Agreement, Roche or Dexcom receives correspondence, notification or inspectional findings, from the FDA or other US governmental or regulatory authority regarding Dexcom’s Services, Records, Dexcom’s quality system, and/or possible audit
or any other matter relating to this Agreement, the Receiving Party shall notify the other Party and provide copies of such correspondence, notification or inspectional findings within forty-eight (48) hours following receipt of such
correspondence, notification or inspectional findings. Dexcom shall permit a representative designated by Roche to be present during any inspection or audit by a governmental or regulatory authority if the inspection or audit is reasonably expected
to relate to the Services. Roche shall have the right to review and participate in drafting any response to any such inspection or audit, or any other request for information from a governmental or regulatory authority pertaining to the Dexcom
Services or any activities under this Agreement, prior to submission of such response to the governmental or regulatory authority. Dexcom shall provide to Roche copies of all information bearing on the Services received from any governmental or
regulatory authority prior to, during, or following any audit or inspection, within two (2) calendar days of receipt. 

13.3 Federal Contractor Status. Roche is a federal contractor with obligations from various federal laws, rules, regulations, and
executive orders, including without limitation, Equal Employment Opportunity and the utilization of small, disadvantaged, woman-owned, veteran and HUB zone businesses. Dexcom agrees to perform the Services required to be performed by it in
compliance with Applicable Laws. Dexcom agrees to provide, at Roche’s request, any and all documentation required to substantiate such compliance. 
 13.4 Development and Regulatory Plan. Roche and Dexcom will collaborate in good faith to create a development plan for the Integrated System (the “Development Plan”). Roche and
Dexcom will collaborate in good faith to create a regulatory plan to seek and maintain regulatory approval to market the Integrated System (the “Regulatory Plan”). The Regulatory Plan shall describe the responsibilities of the
Parties in seeking and maintaining regulatory approval of the Integrated System. Upon mutual agreement of the Parties, the Parties will update the Development Plan and Regulatory Plan detailing each Party’s roles and responsibilities, major
milestones and measurable events required to develop the Integrated System and obtain regulatory approval of the Integrated System and such plans will be incorporated into this Agreement as Exhibits to the applicable Statement of Work. The Parties
shall use good faith efforts to negotiate and execute amendments to this Agreement, to the extent necessary to include any additional terms and conditions required to implement the Development Plan, Regulatory Plan or any amendments to the
Development Plan or Regulatory Plan, including without limitation, those regulatory and quality provisions deemed reasonably necessary by the Party submitting any applications required by Applicable Law. 

 

	 	14.	[INTENTIONALLY OMITTED] 

  
 Page
19 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

	 	15.	Records and Audits 

 15.1
Records. In compliance with Applicable Laws and its own internal quality systems, Dexcom shall maintain reproducible records of all information and data relating to its performance under this Agreement (the “Records”)
including, without limitation, information described or requested in the applicable Statement of Works, Work Products, accounting records, time sheets, written policies and procedures, correspondence, and any other documentation until the later of
five years after the expiration or earlier termination of this Agreement and the period required by any Applicable Laws. Dexcom’s internal quality systems respecting the creation and maintenance of records shall comply with 21 CFR 820, as
applicable and 21 CFR part 11 regarding electronic records and signatures. 
 15.2 Audit of Dexcom. Within forty eight
(48) hours after a request is made by Roche, Dexcom’s facilities and any work in progress or Work Products produced hereunder shall be open to audit, inspection, examination and evaluation, during normal working hours and at reasonable
intervals, by Roche or its authorized representatives to the extent reasonably necessary to evaluate Dexcom’s compliance with, and the conformance of the Work Products to, Applicable Laws, quality assurance requirements, regulatory requirements
and other requirements of this Agreement in connection with its performance under this Agreement Without limiting the generality of the foregoing, Dexcom shall permit Roche or its authorized representatives, to enter the Dexcom’s facilities to
inspect and audit and to make copies of any Records (including without limitation Records relating to quality assurance and regulatory compliance). For the purpose of such audits, inspections, examinations, and evaluations, Roche or its authorized
representatives shall have access to such Records beginning on the Effective Date and continuing until five (5) years after the later of (i) the termination or expiration of the Agreement or (ii) the satisfaction of Dexcom’s
obligations under this Agreement. Dexcom shall cooperate and facilitate such inspection, including without limitation by making Personnel that provided Services under this Agreement available for questioning and demonstrations. In addition, Dexcom
shall provide adequate and appropriate workspace for Roche or its authorized representatives to conduct such audits, inspections, examinations and evaluations. 
 15.3 Ownership and Maintenance of Records. Dexcom shall notify Roche in writing at the expiration of the time period specified for access to the Records set forth in Section 15.2 or at any
time thereafter, if it does not intend to maintain the Records. Roche shall have sixty (60) calendar days thereafter to respond to such notice. If Roche determines that it requires such Records, Roche shall notify Dexcom and such Records shall
be shipped to Roche within a reasonable period of time, but in no event later than sixty (60) calendar days after such notification from Roche. Roche agrees to pay for reasonable retrieval and shipping costs associated with such Records.

  

	 	16.	Miscellaneous 

 16.1
Assignability. Neither this Agreement nor any interest hereunder shall be assigned by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld. This Agreement shall be binding upon
and inure to the benefit of the legal successors to the parties hereto. 

  
 Page
20 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 16.2 Entire Agreement. This Agreement, including any Statements of Work issued
hereunder embodies the entire understanding and agreement among the Parties and supersedes all previous negotiations, representations, writings and agreements, written, or oral, with respect to the subject matter herein. Any additional terms or
conflicting terms or conditions contained in any other document pursuant to the subject matter herein, including any purchase order or invoice, are hereby superseded. Dexcom and Roche agree that this Agreement shall not be altered, amended or
modified, except in writing that is signed by an authorized representative of both Roche and Dexcom. In the event of any conflict between a Statement of Work and this Agreement, the terms and conditions of this Agreement shall govern. 

16.3 Enforceability. This Agreement, when executed and delivered by Dexcom and Roche shall be a legal, valid and binding
obligation, enforceable against such Parties in accordance with the terms of this Agreement. Any Statements of Work issued hereunder when executed and delivered by Dexcom and Roche, shall be a legal, valid and binding obligation, enforceable against
Dexcom and Roche. 
 16.4 Non-Waiver. No term or provision hereof shall be deemed waived and no breach excused unless
such waiver or consent shall be in writing and signed by a duly authorized representative of the Party claimed to have waived or consented. 
 16.5 Cumulative Remedies. Any rights of cancellation, termination, liquidated damages, or other remedies provided in this Agreement or any Statement of Work are cumulative and are not intended to
be exclusive of any other remedies to which the injured Party may be entitled at law or equity (including but not limited to the remedies of specific performance and cover). The use of one or more available remedies shall not bar the use of any
other remedy for the purpose of enforcing the provisions of this Agreement; provided, however, that a Party shall not be entitled to retain the benefit of inconsistent remedies. 

16.6 Severability. If any provision of this Agreement is invalid or unenforceable under any statute or rule or law, the provision
is to that extent to be deemed omitted, and the remaining provisions shall not be affected in any way. 
 16.7 Independent
Relationship of the Parties. Dexcom and Roche intend that an independent contractor relationship shall be created by this Agreement, and nothing herein shall be construed as creating an employer/employee relationship, partnership, joint venture,
or concerted action. 
 16.8 Notices. All notices, consents, waivers and other communications required or permitted by
this Agreement shall be in writing and shall be deemed given to a Party when (a) delivered to the appropriate address by hand or by nationally recognized overnight courier service (costs prepaid); (b) sent by facsimile or e-mail with
confirmation of transmission by the transmitting equipment; or (c) received or rejected by the addressee, if sent by certified mail, return receipt requested, in each case to the following addresses, facsimile numbers or e-mail addresses and
marked to the attention of the person (by name or title) designated below (or to such other address, facsimile number, e-mail address or person as a Party may designate by notice to the other Parties): 

  
 Page
21 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

  

			
	            if to Roche to:	  	Roche Diagnostics Operations, Inc.
		  	9115 Hague Road
		  	Indianapolis, Indiana 46250
		  	Attn: Purchasing Manager
		  	Fax No.: (317) 521-4287
		
	            with a copy to:	  	Roche Diagnostics Operations, Inc.
		  	9115 Hague Road
		  	Indianapolis, Indiana 46250
		  	Attn: Law Department
		  	Fax No.: (317) 521-2840
		
	            if to Dexcom to:	  	Dexcom, Inc.
		  	6340 Sequence Drive
		  	San Diego, CA 92121
		  	Attn: President
		  	Fax No.: (858) 200-9563
		
	            with a copy to:	  	Dexcom, Inc.
		  	6340 Sequence Drive
		  	San Diego, CA 92121
		  	Attn: Legal
		  	Fax No.: (858) 875-5324

 16.9 Publicity. Except as may be required by any rules and regulations promulgated by the
Securities and Exchange Commission, or any national securities exchange on which either Party’s securities are traded, neither Party shall use the other Party’s name or trademarks, or refer to or disclose the existence of this Agreement or
the obligations performed hereunder, directly or indirectly, without the prior written consent of such Party. 
 16.10
Governing Law; Venue. The Agreement shall be governed by the laws of the United States and the laws of the state of Delaware, without regard to the conflicts of law principles thereof. Both Parties agree to use reasonable efforts in a good
faith attempt to settle as promptly as possible any and all disputes arising from this Agreement or a transaction conducted pursuant to this Agreement. 
 [signature page follows] 
  

 
  

  
 Page
22 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 IN WITNESS WHEREOF, Roche and Dexcom
hereto have caused this Agreement to be executed by their duly authorized representatives. 
  

									
	DEXCOM,
INC.                            	 		 	ROCHE DIAGNOSTICS OPERATIONS,
INC.                    
					
	By:	 	  
	 		 	By:	 	  

		 	  
	 		 		 	 Brian Heald

		 	             (printed)	 		 		 	             (printed)
	Title:	 	  
	 		 	Title:	 	Vice President, DC Development & Mfg
	Date:	 	                             
                                         
                              	 		 	Date:	 	                             
                                         
                              

  
 Page
23 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 EXHIBIT A 
 STATEMENT OF WORK 
 This Statement of Work (“SOW”) is entered into by the Roche
Diagnostics Operations, Inc. (“Roche” or “Purchaser”) and Dexcom, Inc. (“Dexcom” or “Developer”) pursuant to the Research and Development Agreement by and between Roche and Developer dated November 1,2011
(the “Agreement”). All terms and conditions of the Agreement apply to this SOW and all capitalized terms used but not otherwise defined in this SOW have the meaning set forth in the Agreement. 

    General Information 
  

			
	Statement of Work Effective Date    	 	

  

			
	 Developer:

 
 Name: Dexcom, Inc
 Address: 6340 Sequence Drive
 San Diego, CA 92121

 
	 	
Purchaser:
  
 Name: Roche Diagnostics Operations, Inc.
 Address: 9115 Hague Road

Indianapolis, IN 46250
  

     Scope of Work & Performance Requirements 

 

	
	
1.      Background:

 
 A.     Dexcom and
Roche intend to create an Integrated System.
  
 B.    
Roche and Dexcom will collaborate in good faith on the design and product specifications of the Integrated System, in order to connect the G5 System and the Accu-Chek Systems, which specifications, when developed, shall be incorporated into this
Statement of Work and attached as Exhibit B, hereto.
  
 2.      Each Party shall be responsible for the following Services:
  

[*****]
  
                                   
                      e.
  

 

  

	
	
3.      The Development Services shall be provided at the following
facilities:
 [*****]

  

	
	
4.      Project Leaders:

[*****]

  
 Page 24 of
30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

	
	 
	 

  

	
	  
 5.      The Services set forth in this SOW shall be rendered by each Party during the Term. This SOW will become effective as of the Effective Date set forth above and shall
remain effective until completion of all obligations set forth in this SOW. The initial estimated timelines for each Party’s deliverables are set forth in Sections 6 and 7 below. [*****]

 

  

	
	  
 6.      The Services shall be provided in accordance with the following estimated schedule, for which the below dates may change as part of finalizing the Development Plan
and Regulatory Plan: [*****]
  

  

	
	 The Services performed by Dexcom shall include the delivery of the
following reports, results, analysis, and other deliverables[*****]
  
 The
list of deliverables set forth above must specify all Developer-generated reports or documents that Roche needs for purposes of compliance with the design control requirements of FDA’s Quality System Regulation, 21 CFR Part 820, Subpart C.
Developer shall only be responsible for creating and delivering these records only when applicable and only to the extent that it is specifically required by FDA’s Quality System Regulation, 21 CFR Part 820, Subpart C. [*****] These documents
may include, but not be limited to, records relating to the following design control steps, to the extent applicable:
  

 ̈       Design and development
planning, 21 CFR § 820.30(b)
  

 ̈       Design input, 21 CFR
§ 820.30(c)
  
  ̈       Design output, 21 CFR § 820.30(d)
  

 ̈       Design review, 21 CFR
§ 820.30(e)
  
  ̈       Design verification, 21 CFR § 820.30(f)
  

 ̈       Design validation, 21
CFR § 820.30(g)
  
  ̈       Design transfer, 21 CFR § 820.30(h)
  

 ̈       Design changes, 21 CFR
§ 820.30(i)
  
 In addition, where applicable, Deliverables should
include documentation of compliance with:
  
  ̈       Good Laboratory Practices, 21 CFR Part 58

 

 ̈       Investigational Device
Exemptions, 21 CFR Part 812
  
  ̈       Good Tissue Practices, 21 CFR Part 1271
  

 ̈       The Clinical
Laboratories Improvement Act, codified at 42 U.S.C. 263a, and regulations promulgated thereunder, 42 CFR Part 493, and
  

 ̈       Any similar regulatory
requirements of any applicable regulatory authority.
  

  
  

 

	
	  
 7.      The following are Key Personnel for Dexcom:
 [*****]
  

  
 Page 25 of
30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

	
	  
 8.      The following are Key Personnel for Roche:
                         [*****]

 

  

	
	  
 9.      The Steering Committee will review the Development Services rendered. Such reviews will be made as outlined below: [*****]

 

  

	
	  
 10.    The Development Services shall meet the following specifications and performance requirements: [*****]
  

     Fees and Payment 

 

													
	 1.      Fees and Payment. The Parties
have agreed to the Fees set forth below for the Development Services set forth in this SOW:
  

 

	Section 1	 	 	  	 Developer shall invoice Purchaser
in accordance with the Agreement and based on the rates set forth in each of the Development and Regulatory Plans.
  
 Roche will pay Dexcom for Services provided by Dexcom in connection with for the Integrated System. Dexcom shall invoice Roche in accordance with the Agreement and based on the rates set forth below,
which may be subject to adjustment based on the mutual agreement of the parties[*****]. All Services shall be provided by Dexcom at a total cost that is estimated to be between $800,000 and not to exceed $1,000,000, subject to adjustment
[*****].
  

	 	 	  	Title	  	Annualized Cost	  	Allocation of EE Time to
Project	  	Annual Charge to
Partner	  	Total Cost
Estimate
	 		  	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 		  	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 		  	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 		  	 [*****]
	  	[*****]	  	[*****]	  		  	[*****]
	 	 		  	 [*****]
	  	[*****]	  	[*****]	  	 	  	[*****]
	 	 		  		  		  	 Total
	  	 	  	[*****]
	 						 
	 	 	 	  	 [*****]

 
	  	 	  	 	  	 	  	 

  
 Page 26 of
30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

			
	Section 2    	  	 Upon
execution of the Agreement, Roche shall receive the licenses set forth in Article 6 of the Agreement.
  
 Dexcom shall invoice Roche after accomplishing the following milestones
  
 Milestone Description and Portion in USD
  
 [*****]
  
 The total
consideration of this entire Section 2 is not to exceed USD $3,000,0000.

	 	  	 

  

	
	  
 2.      Travel Expenses. [*****]
  

  

	
	  
 3.      Other Expense. Any other potential fees by Dexcom must be quoted to Roche and approved by Roche via Purchase Order before they can be
rendered.
  

 IN WITNESS WHEREOF, Purchaser and Developer have caused this SOW to
be executed by their duly authorized representatives. 
  

									
	DEXCOM, INC.                	 		 	ROCHE DIAGNOSTICS OPERATIONS,
INC.            
					
	By:	 	  
	 		 	By:	 	  

		 	  
	 		 		 	 Brian Heald

		 	(printed)	 		 		 	(printed)
	Title:	 	  
	 		 	Title:	 	 Vice President, DC Development & Mfg

	Date:	 	                             
                                         
                                	 		 	Date:	 	                             
                                         
                                

  
 Page 27 of
30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS
BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 EXHIBIT B 
 INTEGRATED SYSTEM SPECIFICATIONS 
 TO BE UPDATED AND AGREED TO AT A LATER
DATE BY THE PARTIES 

  
 Page
28 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS
BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 EXHIBIT C 
 DEVELOPMENT PLAN  
 TO BE UPDATED AND AGREED TO AT A LATER DATE BY THE
PARTIES 

  
 Page
29 of 30 

 ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS
BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS 
  

 Exhibit D 
 REGULATORY PLAN 
 TO BE UPDATED AND AGREED TO AT A LATER DATE BY THE
PARTIES 

  
 Page
30 of 30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]